Icosavax Reports Second Quarter 2022 Financial Results and :

– Announced positive topline interim Phase 1/1b results for VLP vaccine candidate IVX-121 against respiratory syncytial virus (RSV) - – Icosavax plans...

Related Keywords

United States , Jessica Yingling , Laurence Watts , Adam Simpson , Institute For Protein Design , Little Dog Communications Inc , Nasdaq , Exchange Commission , Icosavax Inc , University Of Washington , Gilmartin Group , Chief Executive Officer , Receptor Binding Domain , Protein Design , Private Securities Litigation Reform Act , Nasdaq Icvx , Icosavax , Nc , Nitgens , Infectious Diseases , Metapneumovirus , Respiratory Syncytial Virus , Vaccine , Ars Cov 2 , Mpv , Rsv , Help ,